> Celgene is buying an active ingredient plant from Switzerland's Siegfried for $46.5 million. Report
> Roche announced that its latest Phase III trial for Xeloda hit its primary endpoint in a study on progression-free cancer survival. Release
> Merck and Vertex announced that MK-0457 will move into Phase II for leukemia after successfully completing a dosing study. Report
> Bristol-Myers Squibb is touting the positive results of a Phase III trial of Sprycel among patients resistant to Gleevec. Report
> AEterna Zentaris has released positive interim data from a mid-stage trial of Perifosine for multiple myeloma. Release
> Biogen Idec released positive Phase I/II data for lumiliximab. Report
> Health Discovery Corporation has executed a license agreement with Pfizer for its pattern recognition technology. Release
> Synerx Pharma has inked an agreement with Teva Pharmaceutical Industries in which Synerx will develop and secure FDA approval for a number of undisclosed products. Release
And Finally… Connecticut is moving aggressively in its support of embryonic stem cell research, handing out $20 million for 21 programs. Report